Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: Potential role for interleukin-6

Atherosclerosis

Volumn 158, Issue 2, 2001, Pages 471-476

  Lee, Tsung Ming ^a   Su, Sheng Fang ^b   Hwang, Juey Jen ^a   Tseng, Chuen Den ^a   Chen, Ming Fong ^a   Lee, Yuan Teh ^a   Wang, Shoei Shen ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c Cardiology Section National Taiwan University Hospital ^*  (Taiwan)

Author keywords

Cilostazol; Interleukin 6; Intermittent claudication; Lipid; Pentoxifylline; Peripheral vascular disease; Phosphodiesterase inhibitor

Indexed keywords

CILOSTAZOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID; PENTOXIFYLLINE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; EXERCISE TOLERANCE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; LIPOGENESIS; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREADMILL EXERCISE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WALKING;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INTERLEUKIN-6; INTERMITTENT CLAUDICATION; LIPIDS; MALE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; TETRAZOLES; TRIGLYCERIDES; VASODILATOR AGENTS;

EID: 0034813229     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00457-9     Document Type: Article

References (30)

1. Epidemiology of atherosclerotic disease in the lower limbs
2. Conservative management of intermittent claudication
3. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
4. Induction of interleukin-1beta and interleukin-6 gene expression in hypoperfused skeletal muscle of patents with peripheral vascular disease
5. The biology of interleukin-6
6. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1
7. Regulation of BSF-2/IL-6 production by human mononuclear cells: Macrophage-dependent synthesis of BSF-2/IL-6 by T cells
8. Liver sinusoidal endothelial cells induce acute phase protein synthesis in cultured guinea pig hepatocytes by release of interleukin 6 (IL-6)
9. Interleukin-6: An overview
10. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects
11. Relation of serum cytokine concentration to cardiovascular risk factors and coronary artery disease
12. Recommended standards for reports dealing with lower extremity ischemia: Version
13. Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease
14. Enzymatic determination of total serum cholesterol
15. A peroxidase-coupled method for colorimetric determination of serum triglycerides
16. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints
17. Transcriptional regulation of the interleukin-6 gene in mesangial cells
18. CAMP inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts
19. Synthesis of interleukin 6 (inteferon-β2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP
20. Differential regulation of TNFα, IL-1β, IL-6, IL-8, TNF-β, and IL-10 by pentoxifylline
21. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A
22. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
23. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease
24. The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha
25. Effect of endotoxin in IL-1β-deficient mice
26. Characterization of tumor necrosis factor-α deficient mice
27. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
28. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
29. Calcium channel blockers activate interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells
30. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys